EC方案序贯多西他赛辅助化疗治疗乳腺癌的临床观察被引量：2

Clinical observation of sequential docetaxel adjuvant chemotherapy in the treatment of breast cancer

下载PDF

导出

摘要目的探讨EC方案序贯多西他赛辅助化疗治疗乳腺癌的临床有效性与安全性。方法以2014年1月至2017年10月本院收治的50例乳腺癌手术患者为研究对象,依据术后化疗方法不同分为两组。观察组25例,予以EC方案(表柔比星+环磷酰胺)序贯多西他赛;对照组25例,予以CEF方案(表柔比星+环磷酰胺+氟尿嘧啶)序贯多西他赛。统计两组治疗期间毒副反应发生率,治疗后随访,观察两组无病生存率和总生存率。结果观察组一年无病生存率(96.0%)、一年总生存率(92.0%)与对照组比较差异无统计学意义;观察组化疗期间消化道症状68.0%,皮肤黏膜症状28.0%,骨髓抑制56.0%,脏器毒性20.0%,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论 EC方案序贯多西他赛辅助化疗是治疗乳腺癌的有效手段,在延长患者生存期方面与CEF方案序贯多西他赛效果相当,但可以显著减少化疗相关毒副反应,对提高患者依从性及化疗期间生活质量具有积极作用,值得推广使用。

作者杨璐

机构地区射阳县人民医院肿瘤治疗中心

出处《当代医学》 2019年第13期177-178,共2页 Contemporary Medicine

关键词乳腺癌 EC方案多西他赛序贯化疗生存率毒副反应

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1王雅婧,刘德权,叶剑桥.多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌临床观察[J].武警医学,2014,25(9):921-923. 被引量：17
2张利东.吡柔比星和环磷酰胺序贯多西他赛治疗腋窝淋巴结阳性乳腺癌的临床效果观察[J].中国现代药物应用,2017,11(9):1-3. 被引量：6
3黄喜文,吴静娜,吴国武,黎佳全.表柔比星、环磷酰胺联合多西他赛新辅助化疗方案对三阴性乳腺癌的疗效观察[J].临床医学工程,2015,22(12):1586-1588. 被引量：13
4卢转飞,林琪,陈明聪,何桂芬.多西他赛、表柔比星及环磷酰胺联合化疗对乳腺癌新辅助化疗患者疗效观察[J].药物流行病学杂志,2015,24(3):136-138. 被引量：12
5李剑,赵二保,畅俊平.表柔比星及环磷酰胺序贯多西他赛联合曲妥珠单抗对乳腺癌患者心功能影响的研究[J].中国药物与临床,2018,18(4):581-582. 被引量：16
6黄恒,崔彬,刘付霖,米明.多西他赛表柔比星联合环磷酰胺与多西他赛联合表柔比星治疗绝经前乳腺癌的疗效比较[J].中国肿瘤临床与康复,2015,22(2):149-151. 被引量：15

二级参考文献58

1王子平,孙燕,张湘茹,张茂宏,王秀问,于学军,南克俊,李恩孝,刘基巍,高亚杰,关小倩,宋恕平,盛立军,王东林,王志新.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2006,28(6):468-470. 被引量：70
2WHO药品不良反应术语集累及的系统-器官代码检索目录[J].中国药物警戒,2007,4(1):58-64. 被引量：35
3Mathew J, Asgeirsson K S, Agrawal A, et al. Neoadju- rant chemotherapy in locally advanced primary breast cancers : the Nottingham experience [ J ]. Eur J Surg On- col, 2007, 33(8) : 972-976.
4Rastogi P, Anderson S J, Bear H D, et al. Preoperative chemo-therapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [ J ]. J Clin Oncol, 2008, 26(16) : 778-785.
5Gupta D, Raina V, Rath G K, et al. Clinical and patho- logical response rates of docetaxel-based neoadjuvant che- motherapyin locally advanced breast cancer arid compari- son with anthracycline-based chemotherapies: eight-year experience from single centre [J ]. Indian J Cancer, 2011,48(4) : 410-414.
6Von Minckwitz G, Kummel S, Vogel P, et al. Intensified neo-adjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study [ J ]. J Natl Cancer Inst, 2008, 100(8) : 552-562.
7Phua C E, Bustam A Z, Yusof M M, et al. Risk of treat- ment related death and febrile neutropaenia with taxane- based adjuvant chemotherapy for breast cancer in a mid- die income country outside a clinical trial setting [ J ]. A- sian Pac J Cancer Prev, 2012, 13(9) : 4623-4626.
8Gianni L, Eiermann W, Semiglazov V, et al. Neoadju- vant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast canc- er (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort [ J ]. Lancet, 2010, 375(9712) :377-384.
9Manne SL,Siegel S,Kashy D,et al.Cancer-specific relationship awareness,relationship communication,and intimacy among couples coping with early stage breast cancer[J].J Soc Pers Relat,2014,31:314-334.
10Printz C.More treatment options for women with hormone receptor-positive breast cancer:guideline update,studies lead to advances in care[J].Cancer,2014,120:2939-2940.